EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparison of CD30L and OX40L Reveals CD30L as a Promising Therapeutic Target in Atopic Dermatitis

Rinkesh K Gupta, Daniela Salgado Figueroa, Ferhat Ay, Benjamin Causton, Shahla Abdollahi, Michael Croft iD

Allergy · 2025

DOI: 10.1111/all.16412 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Allergy, 2025. Verfasst von Rinkesh K Gupta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, OX40 Ligand, CD30 Ligand, Ki-1 Antigen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, La Jolla Institute for Immunology, Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Blocking IL‐13 is highly efficacious in patients with Th2‐biased atopic dermatitis (AD), and recent clinical data have highlighted that targeting the T cell costimulatory molecules OX40 and OX40L (TNFSF4) holds promise for future treatment of AD.

Aim

We asked whether targeting another T cell costimulatory molecule, CD30L (TNFSF8), might also be a possible treatment option in AD.

Methods

Single‐cell RNA‐seq data from human AD skin lesions was analyzed to identify pathogenic IL‐13‐ or IL‐22‐producing T cells and assess expression of CD30 and its ligand in comparison to OX40 and its ligand. Additionally, a murine model of AD with repetitive exposure to house dust mite allergen was used to compare neutralizing antibodies against CD30L with those against IL‐13 or OX40L.

Results

Analysis of several scRNA‐seq datasets from skin lesions of AD patients showed that transcripts for CD30 or CD30L were found expressed with OX40 or OX40L in the primary T cell populations that also expressed mRNA for IL13 and/or IL22 . Suggesting that this could be therapeutically relevant, mice treated prophylactically with a blocking CD30L antibody were protected from developing maximal allergen‐induced AD features, including epidermal and dermal thickening, immune cell infiltration, and expression of AD‐related genes, similar to mice treated with a blocking IL‐13 antibody. Moreover, therapeutic neutralization of CD30L in mice with experimental AD also reduced all of the pathological skin lesion features to a comparable extent as blocking OX40L.

Conclusion

These data suggest that targeting the CD30–CD30L axis might hold promise as a future therapeutic intervention in human AD, similar to targeting the OX40–OX40L axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicOX40 LigandCD30 LigandKi-1 AntigenHumansAnimalsMiceDisease Models, AnimalReceptors, OX40T-Lymphocytes

Stichwörter der Autor:innen

CD30OX40TNFdermatitisinflammationskintherapy

Substanzen

OX40 LigandCD30 LigandKi-1 AntigenTNFSF4 protein, humanReceptors, OX40

Autor:innen und Institutionen

  • Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.
  • Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, California, USA.
  • Department of Pediatrics, University of California San Diego, La Jolla, California, USA.
  • Bristol Myers Squibb, Cambridge, Massachusetts, USA.
  • Department of Medicine, University of California San Diego, La Jolla, California, USA.

ORCID-Profile: Michael Croft

Förderung

  • NIGMS NIH HHS
  • La Jolla Institute for Immunology
  • Bristol-Myers Squibb

Zitieren

APA

Gupta, R. K., Figueroa, D. S., Ay, F., Causton, B., Abdollahi, S., & Croft, M. (2025). Comparison of CD30L and OX40L Reveals CD30L as a Promising Therapeutic Target in Atopic Dermatitis. Allergy. https://doi.org/10.1111/all.16412

Vancouver

Gupta RK, Figueroa DS, Ay F, Causton B, Abdollahi S, Croft M. Comparison of CD30L and OX40L Reveals CD30L as a Promising Therapeutic Target in Atopic Dermatitis. Allergy. 2025. doi:10.1111/all.16412

BibTeX
@article{Gupta2025,
  author = {Gupta, Rinkesh K and Figueroa, Daniela Salgado and Ay, Ferhat and Causton, Benjamin and Abdollahi, Shahla and Croft, Michael},
  title = {Comparison of CD30L and OX40L Reveals CD30L as a Promising Therapeutic Target in Atopic Dermatitis},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.16412}
}
Kostenlos starten →